Back to Results

Cipher Pharmaceuticals Inc (CPHRF)

Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company based in Mississauga, Ontario. The company markets a range of prescription products, including Epuris for severe acne, Actikerall for actinic keratosis, Vaniqa for reducing unwanted facial hair growth in women, Durela for pain management, Brinavess for the conversion of recent-onset atrial fibrillation, Aggrastat for acute coronary syndrome, and Natroba for the topical treatment of head lice and scabies. Its licensed portfolio also includes Absorica, Conzip, and Lipofen. Cipher’s development pipeline includes piclidenoson CF-101 for plaque psoriasis and rheumatoid arthritis, MOB-015 for onychomycosis, and DTR-001, a tattoo removal cream. Founded in 2000, the company’s common stock is listed on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-CPHR.F
$9.20
-10.2% Downside
Fair
Not available
Not available
Great
0.0%
November 5, 2026
9.0x
1.9x
5.3x
262.5 M
251.7 M
0.1%
58.4%
18.7
93.2%
Valuation • Fair Value

Cipher Pharmaceuticals Inc (OTC-CPHR.F) Fair Value by Valuation Model

Review the available estimates for Cipher Pharmaceuticals Inc (OTC-CPHR.F), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$9.20

Estimated downside of 10.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$10.05

Discounted cash flow valuation reference.

Ben Graham Formula Value

$12.66

Classic Ben Graham valuation formula reference.

EPV Fair Value

$7.90

Earnings power value estimate.

Comps Fair Value

$8.57

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for Cipher Pharmaceuticals Inc (OTC-CPHR.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cipher Pharmaceuticals Inc (OTC-CPHR.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

49.623 M

Current operating scale indicator.

Revenue Forecast

50.886 M

Forward revenue estimate.

EBITDA

26.48 M

Current operating profitability reference.

EBITDA Forecast

29.541 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cipher Pharmaceuticals Inc (OTC-CPHR.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cipher Pharmaceuticals Inc (OTC-CPHR.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.22

No elevated caution signal from this screen.

Altman Z-Score

18.7

Relatively strong balance-sheet zone.

FCF / Net Income

93.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cipher Pharmaceuticals Inc (OTC-CPHR.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cipher Pharmaceuticals Inc (OTC-CPHR.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

44

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cipher Pharmaceuticals Inc (OTC-CPHR.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cipher Pharmaceuticals Inc (OTC-CPHR.F) Stock Forecast & Technical Outlook

Review Cipher Pharmaceuticals Inc (OTC-CPHR.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cipher Pharmaceuticals Inc (OTC-CPHR.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Cipher Pharmaceuticals Inc (OTC-CPHR.F) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ • Fast Investor Answers

Cipher Pharmaceuticals Inc (OTC-CPHR.F) Stock FAQ

Data-supported answers about Cipher Pharmaceuticals Inc (OTC-CPHR.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$9.20
Estimated downside 10.2%
Valuation Rating
Overvalued
Estimated downside of 10.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is $9.20. This implies an estimated downside of 10.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 10.2% versus the current market price.

The current financial health read for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is November 5, 2026.

The latest available data indicates no current dividend yield for Cipher Pharmaceuticals Inc (OTC-CPHR.F).

The current P/E ratio listed for Cipher Pharmaceuticals Inc (OTC-CPHR.F) is 9.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cipher Pharmaceuticals Inc is 262.5 M.

The current enterprise value listed for Cipher Pharmaceuticals Inc is 251.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cipher Pharmaceuticals Inc is OTC-CPHR.F, and the stock is listed on OTC Markets.

Cipher Pharmaceuticals Inc (OTC-CPHR.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Cipher Pharmaceuticals Inc is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cipher Pharmaceuticals Inc is 58.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B